# KURA ONCOLOGY, INC. (KURA) · Edgar & Edgarette company card

> Kura Oncology (KURA) grew revenue 25.2% in FY2025 to $67 million, operating margin -450% against a -3.8% median for pharmaceutical preparations, equity 23.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1422143 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/KURA) · [JSON](https://www.pops4.com/boards/company/KURA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $67M |
| Revenue growth, 1 year | 25.2% |
| Revenue growth per year | — |
| Operating margin | -449.9% (prior year -358.5%) |
| Net margin | -412.9% |
| Operating cash flow | −$64M |
| Capital spending | $7M |
| Free cash flow | −$71M |
| Cash | $149M |
| Long-term debt | $10M |
| Total assets | $738M |
| Total equity | $174M |
| Equity ÷ assets | 23.6% |
| Return on equity | -160.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.37 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -449.9% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $67.5M (FY2025), total debt $9.7M. Experience: revenue up 25.2% on the year; operating margin -449.9%, down from -358.5%. Soundness: equity 23.6% of assets, return on equity -160.0%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $62.0M and $111.4M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -449.9% against a -3.8% median; growth 25.2% against 13.7%.

Range logged 2026-09-20, receipt e6c31ff9d424dab4, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-09-08 ([filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526384363/0001193125-26-384363-index.htm))

## Recent filings

- 8-K · filed 2026-09-09 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/0001193125-26-385881-index.htm)
- 8-K · filed 2026-09-08 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526384363/0001193125-26-384363-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526346884/0001193125-26-346884-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/0001193125-26-346856-index.htm)
- 8-K · filed 2026-07-29 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526324202/0001193125-26-324202-index.htm)
- 8-K · filed 2026-06-04 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001422143.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1422143

## Cite

POPS4, Edgar & Edgarette: KURA ONCOLOGY, INC. (KURA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/KURA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.